Sumitomo Pharma

Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update

Retrieved on: 
星期四, 五月 16, 2024
Biotechnology, Diabetes, Other Health, Health, Pharmaceutical, DSM-IV codes, Merck Serono, JPY, Serono, Sumitomo Pharma, NASH, EUR, Fatty liver disease, Merck, FY, Pharmaceutical industry

Thomas Kuhn, Chief Executive Officer of Poxel, stated: “TWYMEEG® continues to demonstrate its effectiveness through its steadily progressively increasing sales in Japan.

Key Points: 
  • Thomas Kuhn, Chief Executive Officer of Poxel, stated: “TWYMEEG® continues to demonstrate its effectiveness through its steadily progressively increasing sales in Japan.
  • Beyond 2024, Poxel expects to receive escalating double-digit royalties as well as additional sales-based payments upon achievement of contractually based sales thresholds.
  • Poxel reported EUR 449 thousand5 revenue for the quarter ended March 31, 2024, similar to the revenue reported during the corresponding period in 2023.
  • Revenue for the first quarter of 2024 reflects JPY 75.9 million (EUR 465 thousand2) of royalty revenue from Sumitomo Pharma, which represents 8% of TWYMEEG® net sales in Japan.

Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release

Retrieved on: 
星期一, 四月 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Clinical Trials, Other Health, USD, Patient, Adenosine, DSM-IV codes, ADPKD, Sumitomo Pharma, Safety, Pharmacokinetics, European Patent Convention, JPY, Merck Serono, Kidney, Male, Adrenoleukodystrophy, VLCFA, EUR, Plasma, Serono, Disease, NASH, Fatty liver disease, Patent, ALD, AMN, POC, Biomarker, Merck, EPO, Pharmaceutical industry

As a result, TWYMEEG gross sales should exceed its FY 2023 guidance of JPY 4.2 billion (EUR 25.7 million)3 driven by a favourable sales trend in Japan.

Key Points: 
  • As a result, TWYMEEG gross sales should exceed its FY 2023 guidance of JPY 4.2 billion (EUR 25.7 million)3 driven by a favourable sales trend in Japan.
  • Beyond 2024, Poxel expects to receive escalating double-digit royalties as well as additional sales-based payments upon achievement of contractually based sales thresholds.
  • For territories not covered by its agreement with Sumitomo Pharma, Poxel is in ongoing discussions with potential partners for Imeglimin.
  • Net financial debt (excluding IFRS16 impacts and derivative debts) was EUR 47.4 million as of March 31, 2024, as compared to EUR 45.6 million as of December 31, 2023.

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

Retrieved on: 
星期二, 四月 2, 2024
Disease, Macular edema, NIU, Paratriathlon, Arm, Rule, Safety, Risk, Webcast, Inflammation, Patient, NEPTUNE, EDT, Master of Science, Haze, Prednisone, Visual acuity, Therapy, Sumitomo Pharma, Calendar, Share repurchase, JAK, Visual impairment, Physician, Hand, Pediatrics, Pharmaceutical industry

We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.

Key Points: 
  • We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.
  • The NEPTUNE study enrolled 26 subjects with active NIU who were randomized 2:1 to brepocitinib 45 mg once daily or brepocitinib 15 mg once daily.
  • All week 24 secondary efficacy endpoints, including haze grades, visual acuity, and macular thickness, were also positive and dose responsive.
  • The presentation and webcast details are also available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.

IDRx Appoints David P. Kerstein, M.D., as Chief Medical Officer

Retrieved on: 
星期三, 三月 27, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Sumitomo Pharma, Takeda Pharmaceutical Company, Tufts University, Patient, Therapy, Takeda, GIST, ARIAD Pharmaceuticals, Pharmaceutical industry

IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced the appointment of David P. Kerstein, M.D., as Chief Medical Officer.

Key Points: 
  • IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced the appointment of David P. Kerstein, M.D., as Chief Medical Officer.
  • Dr. Kerstein brings to IDRx deep experience in early- and late-stage oncology drug development, including multiple precision oncology medicines.
  • He joins the founding IDRx R&D leadership team of Jessica Christo, Chief Development Operations Officer, and Vivek (Vic) Kadambi, Ph.D., Chief Product Development Officer.
  • Before Theseus, Dr. Kerstein served as Chief Medical Officer of Anchiano Therapeutics Ltd.

Exscientia Business and Financial Update for the Full Year 2023

Retrieved on: 
星期四, 三月 21, 2024
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Research, Federal Reserve Bank, Automation, Ovarian cancer, DSM-IV codes, CDK7, Learning, LSD1, Bill, Half-life, UGT1A1, International, Inflammation, Patient, EDT, G&A, Cancer, AI, Bristol Myers Squibb, IND, Medicine, Merck Group, Sumitomo Pharma, PKC, ID, GMT, MALT1, Acute leukemia, Pharmaceutical industry

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below.

Key Points: 
  • Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below.
  • Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30 a.m. EDT.
  • This study has the potential to support the ongoing development of ‘539, Exscientia’s LSD1 inhibitor
    In July 2023, Exscientia launched EXCYTE-1, a first-of-its-kind prospective observational study in ovarian cancer.
  • A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website .

Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update

Retrieved on: 
星期四, 二月 15, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Merck, Kidney, USD, POC, Adrenoleukodystrophy, Merck Serono, EPO, JPY, AMN, Sumitomo Pharma, European Patent Convention, Safety, Biomarker, EUR, ALD, ADPKD, Serono, Adenosine, Pharmacokinetics, Patent, Fatty liver disease, Patient, Diabetes, Disease, NASH, Plasma, Male, DSM-IV codes, VLCFA, Pharmaceutical industry

Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.

Key Points: 
  • Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.
  • We’ve also progressed our advanced discussions – in some cases on an exclusive basis – with several potential partners for each of our three proprietary products.
  • Based on this conservative assumption, Poxel expects to receive 8% royalties on TWYMEEG® net sales.
  • As of December 31, 2023, total cash and cash equivalents were EUR 2.3 million (USD 2.6 million)1, as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

Poxel Provides Corporate Update

Retrieved on: 
星期四, 十二月 21, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IRIS, Imeglimin, NASH, Sumitomo Pharma, Fatty liver disease, DSM-IV codes, Pharmaceutical industry

POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, provides a corporate update.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, provides a corporate update.
  • With the priority objective of relaunching its R&D activities and executing its strategic plan in rare diseases, the Company has focused in recent months on securing additional financing, in particular non-dilutive solutions.
  • In this context, the Company entered into exclusive negotiations with a leading investor to monetize royalties from TWYMEEG® (Imeglimin) sales in Japan.
  • Poxel’s goal is to finalize one or more of these financing options and/or partnerships by the end of the first quarter of 2024.

Exscientia Business Update for Third Quarter 2023

Retrieved on: 
星期四, 十一月 9, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Research, Drug design, GBP, NSCLC, IND, MALT1, ESMO, Ovarian cancer, International, GMT, EST, Congress, Head, European Society for Medical Oncology, G&A, PKC, Colorectal cancer, Acute leukemia, Acquisition, Federal Reserve Bank, BMS, Growth, CDK7, ID, Risk, Bristol Myers Squibb, Jaundice, Merck Group, Pancreatic cancer, AlphaFold, Sumitomo Pharma, Lung cancer, LSD1, USD, AI, Berlin, Patient, Toxicity, AML, Automation, Pharmaceutical industry, Medical imaging, Rare-earth element, Fine chemical, Cryptocurrency, Bank, Sanofi

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below.

Key Points: 
  • Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below.
  • Exscientia will host a conference call Thursday, November 9 at 1:30 p.m. GMT / 8:30 a.m. EST.
  • A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website .
  • The increase in revenue quarter over quarter was primarily due to $8.38 million in revenue recognised from the projects that Exscientia and BMS mutually determined not to proceed with further development of under the BMS collaboration.

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2023

Retrieved on: 
星期三, 十一月 8, 2023
Biotechnology, Pharmaceutical, Health, Adrenoleukodystrophy, Patient, Serono, ALD, Plasma, AMN, Patent, Biomarker, Sumitomo Pharma, Diabetes, Merck, SGLT2, Jaguar 3.4 Litre, EPO, Pharmacokinetics, Male, DPP4, Disease, Prescription, Marshal of France, Pioglitazone, European Patent Office, EUR, United States patent law, Merck Serono, VLCFA, Safety, European Patent Convention, JPY, Estonia, Kidney, POC, Pharmaceutical industry, Imeglimin

Sumitomo Pharma has worked diligently to increase the production and secure inventory capacity to meet this increasing demand.

Key Points: 
  • Sumitomo Pharma has worked diligently to increase the production and secure inventory capacity to meet this increasing demand.
  • For the Sumitomo Pharma FY 2023, as a conservative assumption in line with Sumitomo Pharma’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • Next Financial Press Release: Fourth Quarter 2023 Cash and Revenue update, on February 15, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV

Retrieved on: 
星期日, 十一月 5, 2023
Slate, Prior, Proxy, United Nations Special Committee on Palestine, Disclosure, Committee, Roivant Sciences, Skadden, Arps, Slate, Meagher & Flom, Mergers and acquisitions, Complaint, Pomerantz, LLP, Special, Sumitomo Pharma

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).

Key Points: 
  • NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Myovant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.